$EQ
Equillium, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018029687 Filed on November 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.000M $30.00K
YoY Change 3233.33%
% of Gross Profit
Research & Development $1.220M $49.95K
YoY Change 2342.49%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $2.226M -$83.71K
YoY Change -2759.15%
Operating Profit -$2.226M -$83.71K
YoY Change 2559.01%
Interest Expense -$2.690M -$60.00K
YoY Change 4383.33%
% of Operating Profit
Other Income/Expense, Net -$2.691M -$57.31K
YoY Change 4594.39%
Pretax Income -$4.920M -$140.0K
YoY Change 3414.29%
Income Tax
% Of Pretax Income
Net Earnings -$4.917M -$141.0K
YoY Change 3386.62%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$444.0K -$8.358K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.000M
YoY Change
Cash & Equivalents $4.983M $732.7K
Short-Term Investments
Other Short-Term Assets $100.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.060M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $31.89K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M
YoY Change
Total Long-Term Assets $1.361M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.060M
Total Long-Term Assets $1.361M
Total Assets $6.422M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.230M
YoY Change
Accrued Expenses $1.449M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.680M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $11.60M
YoY Change
Other Long-Term Liabilities $148.7K
YoY Change
Total Long-Term Liabilities $148.7K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.680M
Total Long-Term Liabilities $148.7K
Total Liabilities $16.80M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $141.7K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.38M
YoY Change
Total Liabilities & Shareholders Equity $6.400M
YoY Change

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$4.917M -$141.0K
YoY Change 3386.62%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$1.640M -$90.00K
YoY Change 1722.22%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.640M -90.00K
Cash From Investing Activities -10.00K 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -1.650M -90.00K
YoY Change 1733.33%
FREE CASH FLOW
Cash From Operating Activities -$1.640M -$90.00K
Capital Expenditures -$10.00K $0.00
Free Cash Flow -$1.630M -$90.00K
YoY Change 1711.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
77805
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
45813
CY2018Q3 us-gaap Assets Current
AssetsCurrent
5060310
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7149366
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31887
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2077
CY2018Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1329350
CY2018Q3 us-gaap Assets
Assets
6421547
CY2017Q4 us-gaap Assets
Assets
7151443
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1230262
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
243741
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1449492
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
325079
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2679754
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
568820
CY2018Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
10321940
CY2017Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
6994847
CY2018Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1274784
CY2017Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1064019
CY2018Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2375109
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
775842
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
148724
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33762
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1962276
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
2225880
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
851313
CY2018Q3 us-gaap Liabilities
Liabilities
16800311
CY2017Q4 us-gaap Liabilities
Liabilities
9403528
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
166
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
124
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
141526
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
9665
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2261874
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2252085
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7151443
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43100000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11130446
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11130446
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49949
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2425213
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1003584
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
220935
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
83711
us-gaap Operating Expenses
OperatingExpenses
4387489
us-gaap Operating Expenses
OperatingExpenses
1072248
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2225880
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-83711
us-gaap Operating Income Loss
OperatingIncomeLoss
-4387489
us-gaap Operating Income Loss
OperatingIncomeLoss
-1072248
CY2018Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1221100
CY2017Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
15123
us-gaap Interest Expense Debt
InterestExpenseDebt
2329296
us-gaap Interest Expense Debt
InterestExpenseDebt
22192
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
27544
us-gaap Investment Income Interest
InvestmentIncomeInterest
57470
CY2018Q3 eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
1496987
CY2017Q3 eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
42191
eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
1599267
eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
61078
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2690543
us-gaap Net Income Loss
NetIncomeLoss
-1155518
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31992
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28057
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
351997
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
33269
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
175181
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
184528
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3699282
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-267417
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25381
eq Deferred Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
1134743
eq Cash Flow Noncash Investing And Financing Activities
CashFlowNoncashInvestingAndFinancingActivities
1142881
eq Cash Flow Noncash Investing And Financing Activities
CashFlowNoncashInvestingAndFinancingActivities
9689
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25381
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1599012
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100
eq Proceeds From Exercise Of Stock Options Including Early Exercise
ProceedsFromExerciseOfStockOptionsIncludingEarlyExercise
199210
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
194607
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1603615
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000100
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2121048
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
732683
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7103553
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4982505
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
732683
us-gaap Stock Issued1
StockIssued1
9689
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8138
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57314
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3871093
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83270
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-4916423
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-141025
us-gaap Net Income Loss
NetIncomeLoss
-8258582
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11078840
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10708074
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10835483
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7127537
us-gaap Profit Loss
ProfitLoss
-8258582
us-gaap Profit Loss
ProfitLoss
-1155518
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3709
us-gaap Share Based Compensation
ShareBasedCompensation
131355
us-gaap Straight Line Rent
StraightLineRent
-487
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2329296
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-22192
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
615091
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of the Company&#8217;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </p></div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M28D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
434280
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
434280
CY2018Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
326165
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15548
CY2018Q3 us-gaap Interest Payable Current
InterestPayableCurrent
478822
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
88372
CY2018Q3 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
58229
CY2017Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
36000
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
184527
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
586276
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
632
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0277
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0293
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8829
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1524672
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1189773

Files In Submission

Name View Source Status
0001564590-18-029687-index-headers.html Edgar Link pending
0001564590-18-029687-index.html Edgar Link pending
0001564590-18-029687.txt Edgar Link pending
0001564590-18-029687-xbrl.zip Edgar Link pending
eq-10q_20180930.htm Edgar Link pending
eq-20180930.xml Edgar Link completed
eq-20180930.xsd Edgar Link pending
eq-20180930_cal.xml Edgar Link unprocessable
eq-20180930_def.xml Edgar Link unprocessable
eq-20180930_lab.xml Edgar Link unprocessable
eq-20180930_pre.xml Edgar Link unprocessable
eq-ex311_46.htm Edgar Link pending
eq-ex312_45.htm Edgar Link pending
eq-ex321_47.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending